natgillin/translations-raw huggingface dataset:
The trials showed that vaccination of pigs with Ingelvac CircoFLEX reduced weight loss in the piglets.
V preskušanjih so ugotovili, da je cepljenje prašičev s cepivom Ingelvac CircoFLEX zmanjšalo izgubo telesne mase pri pujskih.
The trials showed that vaccination of pigs with Porcilis PCV helps to reduce the amount of virus in the animal’s blood and lymphoid tissues and to reduce weight loss associated with PCV2 infection occurring during the fattening period.
Preskušanja so pokazala, da cepljenje prašičev z zdravilom Porcilis PCV pomaga zmanjšati količino virusov v krvi živali in njenih limfnih tkivih ter zmanjšati hujšanje pri okužbi s PCV2 v obdobju pitanja.
The trial’s primary outcome measure was the time to first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction (MI), or non-fatal stroke.
Primarno merilo izida preskušanja je bil čas do pojava srčnožilne (CV) smrti, ne-smrtnega miokardnega infarkta (MI) ali ne-smrtne možganske kapi.
The triphosphate has selective inhibitory activity against HIV-1 and HIV-2 replication in vitro; it is also active against zidovudine-resistant clinical isolates of HIV.
Trifosfat je selektivni zaviralec replikacije virusov HIV-1 in HIV-2 in vitro, učinkuje tudi na klinične izolate virusa HIV, ki so odporni na zidovudin.
The Triumeq pack includes an Alert Card to remind you and medical staff about hypersensitivity.
Pakiranje zdravila Triumeq vsebuje Opozorilno kartico za bolnika kot opozorilo vam in medicinskemu osebju o preobčutljivosti.
The Triumeq pack includes an Alert Card, to remind you and medical staff about hypersensitivity reactions.
Pakiranje zdravila Triumeq vsebuje Opozorilno kartico za bolnika kot opozorilo vam in medicinskemu osebju o preobčutljivostnih reakcijah.
The Trizivir pack includes an Alert Card, to remind you and medical staff about hypersensitivity reactions.
Pakiranje zdravila Trizivir vsebuje opozorilno kartico kot opozorilo o preobčutljivosti na abakavir za vas in medicinsko osebje.
The trough levels should be maintained above 5 g/l.
Najnižje ravni je treba ohraniti nad 5 g/l.
The trough levels should be maintained above 5 g/l.
Najnižje ravni je treba vzdrževati nad 5 g/l.
The trough to peak effects measured by cuff during office visits were 68 % and 76 % for irbesartan/hydrochlorothiazide 150 mg/12.5 mg and irbesartan/hydrochlorothiazide 300 mg/12.5 mg, respectively.
68 %, pri tistih, ki so dobivali kombinacijo irbesartana in hidroklorotiazida 300 mg/12,5 mg, pa 76 %.
The trough to peak effects measured by cuff during office visits were 68% and 76% for Ifirmacombi 150 mg/12.5 mg and Ifirmacombi 300 mg/12.5 mg, respectively.
150 mg/12,5 mg, to razmerje 68 %, pri tistih, ki so dobivali zdravilo Ifirmacombi 300 mg/12,5 mg, pa 76 %.
The Trudexa pre-filled syringe is a glass syringe with needleguard containing a solution of adalimumab.
Napolnjena injekcijska brizga je steklena brizga s ščitnikom za iglo, ki vsebuje raztopino adalimumaba.
The Trudexa syringe should NEVER be reused.
Brizge s Trudexo NIKDAR ne smete ponovno uporabiti.
The tube should be closed tightly after each use.
Po vsaki uporabi tubo tesno zaprite.
The tubular injury was reversible, but not all animals had yet reached full recovery 4 weeks after the end of treatment.
Tubularna poškodba je bila reverzibilna vendar pa niso vse živali dosegle popolnega okrevanja v 4 tednih po koncu zdravljenja.
The Turbospin device should be discarded after completion of the treatment pack.
Ko porabite vso zdravilo v pakiranju, pripomoček Turbospin zavrzite.
The turkey herpesvirus in the vaccine has been modified so that it will produce the fusion protein which forms part of the outer coat of ND virus.
Puranji virus herpesa v cepivu je bil spremenjen tako, da ustvari fuzijski protein, ki tvori del zunanje ovojnice virusa bolezni Newcastle.
The TVC-naïve is a subset of the TVC that includes women with normal cytology, and who were HPV DNA negative for 14 oncogenic HPV types and seronegative for HPV-16 and HPV-18 at baseline.
Naivna TVC je podskupina TVC, ki vključuje ženske, ki so imele normalno citologijo, so bile HPV- DNA-negativne za 14 onkogenih tipov HPV in seronegativne za HPV-16 in HPV-18 ob izhodišču.
The twist-and-use cap should be rotated clockwise or counter clockwise one full turn.
Zaporko zavrtite v smeri urnega kazalca ali v nasprotni smeri urnega kazalca za en cel obrat.
The two active ingredients in Ifirmacombi work together to lower blood pressure further than if either was given alone.
Zdravilni učinkovini v zdravilu Ifirmacombi znižujeta krvni tlak, in to še bolj, kot če bi jemali vsako učinkovino posebej.
The two active substances in Budesonide/Formoterol Teva Pharma B.V. are well known and are present in several medicines used to treat asthma, either alone or in combination with other medicines.
Zdravilni učinkovini v zdravilu Budesonide/Formoterol Teva Pharma B.V. sta dobro znani in sta prisotni v več zdravilih, ki se samostojno ali v kombinaciji z drugimi zdravili uporabljajo za zdravljenje astme.
The two active substances in Procox interact with different parts of the parasites systems.
Zdravilni učinkovini v zdravilu Procox učinkujeta na različne dele organizma zajedavcev.
The two active substances in Qtern work in different ways to help control the level of sugar in your blood and remove excess sugar from your body via your urine.
Zdravilni učinkovini v zdravilu Qtern delujeta na različna načina in tako pomagata uravnati koncentracijo krvnega sladkorja in odstraniti odvečni sladkor iz telesa z urinom.
The two active substances in Synjardy work in different ways to lower this, and thus to control symptoms of the disease.
Zdravilni učinkovini v zdravilu Synjardy jih zmanjšujeta na različna načina in tako nadzorujeta simptome te bolezni.
The two active substances work together to control blood sugar levels in adult patients with a form of diabetes called ‘type 2 diabetes mellitus’.
Dve zdravilni učinkovini urejata raven krvnega sladkorja pri odraslih bolnikih s sladkorno boleznijo tipa 2.
The two co-primary endpoints were percent change from baseline body weight and the proportion of subjects achieving ≥5% total decreased body weight.
Sočasna primarna cilja sta bila odstotna sprememba glede na izhodiščno telesno maso in delež preiskovancev, ki so skupno zmanjšali telesno maso za ≥5 %.
The two doses of Tasigna should be taken around 12 hours apart.
Odmerka zdravila Tasigna je treba vzeti v približno 12-urnem presledku.
The two doses of the vaccine must have been given by the age of 24 weeks, although they should preferably have been given before 16 weeks of age.
Oba odmerka cepiva mora prejeti, preden dopolni 24 tednov, najbolje pa je, da ju prejme že pred dopolnjenim 16 tednom starosti.
The two doses should be taken at around the same time each day.
Ta dva odmerka vsak dan vzemite približno ob istem času dneva.
The two exacerbations studies MEA112997 and MEA115588 enrolled a total of 1192 patients, 60% females, with a mean age of 49 years (range 12– 82).
Dve študiji poslabšanj (MEA112997 in MEA115588) sta skupaj zajeli 1192 bolnikov, 60 % žensk, s povprečno starostjo 49 let (razpon: od 12 do 82).
The two groups also had similar rises in CD4 cell counts.
V obeh skupinah je prišlo tudi do podobnega povečanja števila celic CD4.
The two initial injections are 150 mg on the first day
Začetni injekciji znašata 150 mg na prvi dan zdravljenja (1. dan) in 100 mg na osmi dan (8. dan).
The two main measures of effectiveness were the owner’s assessment of the dog’s behaviour at least two hours after the last dose compared to the previous year and the score given by the owner for signs of anxiety and fear after treatment.
Glavni merili učinkovitosti sta bili lastnikova ocena vedenja psa najmanj dve uri po zadnjem odmerku v primerjavi s prejšnjim letom ter lastnikova ocena znakov tesnobe in strahu po zdravljenju.
The two other active substances in Teysuno allow tegafur to be effective at lower doses and with fewer side effects: gimeracil by preventing the breakdown of 5-FU and oteracil by reducing the activity of 5- FU in normal, non-cancerous tissue in the gut.
Drugi dve zdravilni učinkovini v zdravilu Teysuno omogočata učinkovitost tegafurja tudi pri manjših odmerkih in z manj neželenimi učinki: gimeracil s preprečevanjem razgrajevanja 5-FU in oteracil z zmanjševanjem delovanja 5-FU v normalnem, nerakavem tkivu prebavil.
The two powders are made up into a ‘suspension’ (a liquid with solid particles in it) with a putty-like consistency, which is implanted in the body.
Dva praška se pripravita v „suspenzijo“ (tekočino, ki vsebuje trdne delce), ki ima vosku podobno sestavo in se vsadi v telo.
The two primary safety studies were randomised, active-controlled trials that enrolled participants aged 11 to 55 years (N=2663) and 19 to 55 years (N=1606), respectively.
Dve primarni študiji o varnosti sta bili randomizirani in aktivno kontrolirani preskušanji.
The two studies at the time of the initial marketing authorisation showed that overall Aflunov produced an acceptable antibody response.
Dve študiji, izvedeni ob prvotni izdaji dovoljenja za promet, sta pokazali, da je cepivo Aflunov na splošno spodbudilo zadovoljiv odziv protiteles.
The two studies were similar in design except that BLISS-76 was a 76-week study and BLISS-52 was a 52-week study.
Študiji sta bili po načrtu podobni, le da je bila študija BLISS-76 76- tedenska študija in študija BLISS-52 52-tedenska.
The two total full body skin examinations per year are intended to:
Namen dveh pregledov kože po celotnem telesu na leto je:
The two treatment groups were similar with regard to the overall incidence of all-grade bleeding events (6.3% in the BR-CAP group and 5.0% in the R-CHOP group) as well as Grade 3 and higher bleeding events (BR-CAP: 4 patients [1.7%]; R-CHOP: 3 patients [1.2%]).
V obeh skupinah pa je bila podobna celokupna pojavnost krvavitev vseh stopenj (6,3% v BR-CAP in 5,0% v R-CHOP) in krvavitev stopnje 3 ali več (BR-CAP: 4 bolniki [1,7%]; R-CHOP: 3 bolniki [1.2%]).
The two treatment groups were well balanced with regard to baseline characteristics and disease status.
Terapevtski skupini sta bili ob začetku zdravljenja dobro uravnoteženi glede na osnovne lastnosti in stanje bolezni.
The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600 mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1 g CellCept twice daily.
Vrsta in pogostnost neželenih učinkov v kliničnih študijah, ki so zajele 92 otrok in mladostnikov, starih od 2 do 18 let, ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan, sta bila podobna neželenim učinkom, opaženim pri odraslih bolnikih, ki so prejemali 1 g zdravila CellCept dvakrat na dan.
The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600 mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1 g mycophenolate mofetil twice daily.
Vrsta in pogostnost neželenih učinkov v kliničnih študijah, ki so zajele 92 otrok in mladostnikov, starih od 2 do 18 let, ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan, sta bila podobna neželenim učinkom, opaženim pri odraslih bolnikih, ki so prejemali 1 g mofetilmikofenolata dvakrat na dan.
The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18°years who were given 600°mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1°g mycophenolate mofetil twice daily.
Vrsta in pogostnost neželenih učinkov v kliničnih študijah, ki so zajele 92 otrok in mladostnikov, starih od 2 do 18 let, ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan, sta bila podobna neželenim učinkom, opaženim pri odraslih bolnikih, ki so prejemali 1 g mofetilmikofenolata dvakrat na dan.
The type and pattern of malignancies reported during the open-label period of the trials were similar to those reported for the double-blind experience.
Novotvorbe, o katerih so poročali med odprtim obdobjem preskušanj so bile po vrsti in vzorcu podobne tistim, o katerih so poročali med dvojno slepim obdobjem.
The Type I glass vial is closed with a grey butyl rubber stopper with a green flip-off seal.
Steklena viala (steklo tipa I) je zaprta s sivim z zamaškom iz butilne gume z zeleno zaporko z varnostnim mehanizmom.
The type of clothes you must wear are: burning feeling on the skin.
Nositi morate sledeče vrste oblačil:
The type of scan used with Neuraceq is called positron- emission tomography (PET).
Vrsta preiskave, pri kateri se uporablja zdravilo Neuraceq, se imenuje pozitronska emisijska tomografija (PET).
The type of side effects of Oncaspar largely coincides with that of native non-pegylated L-asparaginase (e.g. native E. coli asparaginase).
Vrsta neželenih učinkov zdravila Oncaspar v veliki meri sovpada z neželenimi učinki nativne nepegilirane L-asparaginaze (npr. nativne asparaginaze iz E. coli).
The type of strain(s) (two strains at most) included in the final product will be selected based on the epidemiological situation at the time of manufacturing and will be stated on the package and in the package leaflet
Tip seva (največ dva seva), ki je vključen v končno zdravilo, je potrebno določiti glede na epidemiološko situacijo ob času proizvodnje cepiva in bo označen na pakiranju in v navodilu za uporabo.
The type of strain(s) (two strains at most) included in the final product will be selected based on the epidemiological situation at the time of manufacturing and will be stated on the package and in the package leaflet.
Tip seva (največ dva seva), ki je vključen v končno zdravilo je potrebno določiti glede na epidemiološko situacijo ob času proizvodnje cepiva in bo označen na pakiranju in v navodilu za uporabo.
The types and incidences of adverse events reported for patients treated with the combination were similar to the adverse event profile for patients on monotherapy.
Pri bolnikih, ki so se zdravili s kombinacijo, so poročali o enaki vrsti in pogostosti neželenih učinkov kot pri bolnikih, ki so se zdravili samo z eno zdravilno učinkovino.
The types of adverse events experienced by patients exposed to supratherapeutic doses were not clinically different from those of patients administered recommended doses of lacosamide.
Vrste neželenih učinkov, ki so jih izkusili bolniki, ki so bili izpostavljeni supraterapevtskim odmerkom se klinično niso razlikovali od tistih, ki so jih izkusili bolniki pri priporočenih odmerkih lakozamida.
The types of adverse events were similar regardless of age.
Vrste neželenih učinkov so bile podobne ne glede na starost.
The types of adverse reactions observed in this population were similar to those previously seen in adults with advanced malignancies involving the bone (see section 4.8).
Vrste neželenih dogodkov, ki so jih opažali v tej populaciji, so bile večinoma podobne tistim, ki so jih prej opažali pri odraslih z napredovalimi malignimi boleznimi, ki zajamejo kosti (glejte poglavje 4.8).
The types of adverse reactions reported during post-marketing with CellCept are similar to those seen in the controlled renal, cardiac and hepatic transplant studies.
Neželeni učinki, ki so se pojavili med trženjem zdravila CellCept, so podobni neželenim učinkom v nadzorovanih raziskavah bolnikov z ledvičnim, srčnim in jetrnim presadkom.
The types of adverse reactions reported during post-marketing with mycophenolate mofetil are similar to those seen in the controlled renal, cardiac and hepatic transplant studies.
Neželeni učinki, ki so se pojavili med trženjem mofetilmikofenolata, so podobni neželenim učinkom v nadzorovanih raziskavah bolnikov z ledvičnim, srčnim in jetrnim presadkom.
The types of adverse reactions reported during post-marketing with mycophenolate mofetil are similar to those seen in the controlled renal, cardiac and hepatic transplant studies.
Neželeni učinki, ki so se pojavili v postmarketinških raziskavah zdravljenja z mofetilmikofenolatom, so podobni neželenim učinkom v nadzorovanih raziskavah bolnikov z ledvičnim, srčnim in jetrnim presadkom.
The types of cancer where Nespo can be used are ‘non-myeloid’ (do not affect the bone marrow).
Zdravilo Nespo se lahko uporablja za „nemieloidne“ vrste rake (tiste, ki ne prizadenejo kostnega mozga).
The types of renal adverse reactions seen with Stribild were consistent with previous experience with tenofovir disoproxil fumarate.
Vrste neželenih učinkov na ledvice, opaženih pri zdravilu Stribild, so bile v skladu s predhodnimi izkušnjami z dizoproksiltenofovirijevim fumaratom.
The types of side effects seen with NeoRecormon depend on the cause of the patient’s anaemia.
Vrste neželenih učinkov, opaženih pri zdravilu NeoRecormon, so odvisne od vzroka bolnikove anemije.
The typical dose is 0.04 to 0.12 mg/kg of patient weight administered twice a day.
Običajni odmerek je od 0,04 do 0,12 mg/kg bolnikove telesne mase dvakrat na dan.
The typical symptoms reported among these cases are similar to those seen with cases of overdose associated with rivastigmine oral formulations.
Značilni simptomi, o katerih so poročali pri teh primerih, so podobni kot pri primerih prevelikega odmerjanja peroralnih oblik zdravila z rivastigminom.
The UCDs include deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH).
Motnje ciklusa sečnine vključujejo pomanjkanje karbamoilfosfat sintaze I (CPS, carbamoyl phosphate-synthase-I), ornitin karbamoiltransferaze (OTC, ornithine carbamoyltransferase), argininosukcinat sintaze (ASS), argininosukcinat liaze (ASL), arginaze I (ARG) in pomanjkanje ornitin translokaze (sindrom hiperornitinemija-hiperamonemija- homocitrulinurija (HHH)).
The ultrasonic properties of the product are very different from those of soft tissue and will generate strong echoes.
Ultrazvočne lastnosti zdravila Luminity se zelo razlikujejo od lastnosti mehkih tkiv in povzročijo močan odboj.
The unadjusted hazard ratio for oral topotecan plus BSC group relative to BSC alone group was 0.64 (95 % CI: 0.45, 0.90).
Nekorigirano razmerje tveganja za skupino s peroralnim topotekanom in NPO glede na skupino s samo NPO je bilo 0,64 (95 % IZ: 0,45, 0,90).
The unadjusted hazard ratio for oral topotecan plus BSC group relative to BSC alone group was 0.64 (95% CI: 0.45, 0.90).
Nekorigirano razmerje tveganj med skupino, ki je prejemala peroralni topotekan in NPO, ter skupino, ki je prejemala samo NPO, je bilo 0,64 (95 % IZ: 0,45, 0,90).
The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin (<35 g/L) as seen in subjects with moderate hepatic impairment.
Delež nevezanega dolutegravirja v plazmi se poveča v primeru nizke koncentracije albumina v serumu (< 35 g/l), kakršna je opazna pri osebah z zmerno okvaro jeter.
The underlying mechanisms are not fully understood, but because of the high doses employed and since Aloxi is intended for single application in humans, these findings are not considered relevant for clinical use.
Odgovorni mehanizmi niso znani, vendar ti podatki zaradi visokih uporabljenih odmerkov in nameravane uporabe zdravila Aloxi kot enkratne aplikacije pri ljudeh klinično niso relevantni.
The underlying nature of these events is uncertain.
Vzrok teh učinkov ni jasen.
The underside of the tray is a “dose preparation guide”.
Spodnja stran podstavka je »vodilo za pripravo odmerka«.
The undesirable effects listed below have been observed following administration of olanzapine.
Neželene učinke naštete spodaj so opazovali po dajanju olanzapina.
The unit is sterile and comes in a sealed, light-proof, aluminium foil laminate pouch, packed in an individual carton box.
Enota je sterilna in pakirana v zavarjeni, proti svetlobi odporni vrečki iz laminata iz aluminijeve folije posamezno v zloženki.
The unopened bag does not require any special storage conditions.
Za shranjevanje neodprtih vrečk niso potrebna posebna navodila.
The unopened bottle does not require any special storage conditions.
Neodprta plastenka: Za shranjevanje zdravila niso potrebna posebna navodila.
The unopened bottle does not require any special storage conditions.
Za shranjevanje neodprte plastenke niso potrebna posebna navodila.
The unopened bottle does not require any special storage conditions.
Za shranjevanje neodprte steklenice niso potrebna posebna navodila.
The unopened vial does not require any specific storage conditions.
Za shranjevanje neodprte viale niso potrebna posebna navodila.
The unopened vial does not require any specific storage conditions.
Za shranjevanje neodprtih vial niso potrebna posebna navodila.
The unopened vial in the original carton protected from light may be stored in a refrigerator (2°C to 8°C) for up to 1 week.
Neodprta viala, shranjena v originalni škatli, zaščitena pred svetlobo je lahko shranjena v hladilniku (2 °C - 8 °C) do 1 tedna.
The updated OS analysis (13 March 2015) demonstrated a statistically significant improvement in OS for the combination compared with vemurafenib monotherapy (Figure 2).
Dopolnjeni rezultati analize celokupnega preživetja (13. marca 2015) so pokazali statistično značilno izboljšanje celokupnega preživetja pri uporabi kombinacije v primerjavi z uporabo vemurafeniba v monoterapiji (slika 2).
The upper bound of one-sided 95% confidence interval (CI) for predicted effect on QTcF at Cmax was 4.8 msec.
Zgornja meja enostranskega 95 % intervala zaupanja (IZ) za predviden učinek na QTcF pri Cmax je bila 4,8 milisekund.
The upper bound of the one-sided 95% CI for the largest placebo- adjusted, baseline-corrected QTc, based on individual correction method (QTcI) for glycerol phenylbutyrate, was below 10 ms, demonstrating that glycerol phenylbutyrate had no QT/QTc prolonging effect.
Zgornja meja enostranskega 95-odstotnega intervala zaupanja za največji, s placebom prilagojeni in za izhodiščne vrednost korigirani QTc, ki temelji na individualni korekcijski metodi (QTcI) za glicerol fenilbutirat, je bila pod 10 ms, kar kaže na to, da glicerol fenilbutirat ni imel učinka na podaljšanje intervala QT/QTc.
the upper outer areas of the buttocks; and the outer area of the upper arms
zgornji zunanji del zadnjice in zunanji del nadlakta
The upper side of the thigh is the preferred site for injection in neonates and infants.
Pri novorojenčkih in dojenčkih je najprimernejše mesto za injiciranje zgornja stran stegna.
The uricase in Krystexxa is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce uricase.
Urikaza v zdravilu Krystexxa se proizvaja z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri bakterija prejme gen (DNK), s katerim lahko tvoriti urikazo.
The urinary excretion of non-liposomal irinotecan is 11% to 20%; SN-38 <1%; and
Izločanje neliposomskega irinotekana z urinom je med 11 in 20 %, SN-38 < 1 % in glukuronida
the urinary tract (structures that carry urine, such as the bladder).
sečila (strukture, po katerih se prenaša urin, na primer mehur).
The urine and faeces radioactivity was mainly excreted during the first 6­8 days, and corresponded to three minor metabolites, respectively.
Radioaktivnost v urinu in blatu se je v glavnem pojavila v prvih 6-8 dneh in je šla na račun treh manj pomembnih presnovkov.
The use in patients with severe renal impairment (CLCR <30 ml/min) is not recommended (see sections 4.4 and 5.2).
Uporaba pri bolnikih s hudo okvaro delovanja ledvic (CLCR <30 ml/min) ni priporočljiva (glejte poglavji 4.4 in 5.2).
The use is not recommended during lactation
Uporaba ni priporočljiva v obdobju laktacije.
The use is not recommended during lactation.
Cepljenje v obdobju laktacije ni priporočljivo.
The use is not recommended during lactation.
Uporaba ni priporočljva v obdobju laktacije.
The use is not recommended during pregnancy.
Uporaba med brejostjo ni priporočljiva.